Phase 1b, Multi-Arm, Open-Label Study Of PDR001 And/or MBG453 In Combination With Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome
MD Anderson Study Status
Decitabine, PDR001, MBG453
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine in AML and high risk MDS patients, and to identify recommended doses for future studies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.